Aldeyra Therapeutics (ALDX) Total Current Liabilities (2013 - 2026)

Aldeyra Therapeutics' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• Quarterly Total Current Liabilities rose 70.28% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (up 70.28% YoY) and the FY2025 annual result came in at $27.8 million, up 49.5% from the prior year.
• Total Current Liabilities was $24.3 million for Q1 2026 at Aldeyra Therapeutics, down from $27.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $29.5 million in Q2 2025 and bottomed at $14.3 million in Q1 2025.
• A 5-year average of $21.0 million and a median of $21.6 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 119.23% — and 2025, when it slumped 34.1%.
• Aldeyra Therapeutics' Total Current Liabilities stood at $15.4 million in 2022, then soared by 44.92% to $22.3 million in 2023, then slipped by 16.43% to $18.6 million in 2024, then surged by 49.5% to $27.8 million in 2025, then dropped by 12.52% to $24.3 million in 2026.
• Business Quant data shows ALDX's Total Current Liabilities at $24.3 million in Q1 2026, $27.8 million in Q4 2025, and $28.5 million in Q3 2025.